Genentech Inc. — Sponsor Intelligence | 35 EU Trials

Filter these 35 trials by condition, phase, country and more.

Open in Search →

35 Registered trials

8 Recruiting

25 Completed trials

16 Countries active

22 Unique IMPs

100% Results reported

Phase II

Phase I

Phase I (Other)

Phase III: 1 Phase II: 8 Phase I/II: 2 Phase I: 12 Phase I (Other): 11 Phase I (FiH): 1

Oversight events:

1 serious breach 1 temporary halt 1 urgent safety measure across 3 trials

View oversight register →

100%

25 of 25 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Breast cancer 3 Obesity 2 Overweight 2 Hormone receptor positive HER2 negative breast cancer 1 Malignant melanoma stage IV 1 PIK3CA-activated mutation 1 Acute kidney injury 1 Colitis ulcerative 1 Glycogen storage disease type II 1 Malignant melanoma stage III 1 Non-small cell lung cancer metastatic 1 Systemic sclerosis pulmonary 1

Top IMPs

ATEZOLIZUMAB 2 GIREDESTRANT 2 VIXARELIMAB 2 AUTOGENE CEVUMERAN 1 EVEROLIMUS 1 EXEMESTANE 1 FULVESTRANT 1 MOSUNETUZUMAB 1 PEMBROLIZUMAB 1 RGT-419B 1 RO7288817 1 RO7837195 1

All trials — page 2

35 total

A Study to Evaluate the Efficacy and Safety of Vixarelimab Compared with Placebo in Patients with Idiopathic Pulmonary Fibrosis and in Patie… Ended

2022-502828-42-00 Phase II 8 countries VIXARELIMAB
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple-Ascending Doses of RO7303509 in Patients with Systemic Sclero… Ended

2022-502981-26-00 Phase I (Other) 6 countries
To Evaluate the Safety and Pharmacokinetics of XMAB24306 in Combination with Daratumumab in Patients with Relapsed/Refractory Multiple Myelo… Ended

2024-510644-31-00 Phase I (Other) 3 countries
A Study to Evaluate the Efficacy and Safety of Astegolimab in Patients With Chronic Obstructive Pulmonary Disease (COPD) Ended

2023-507093-40-00 Phase II 11 countries
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Belvarafenib as a Single Agent and in Combination with Either Cobimetinib … Ended

2022-503107-21-00 Phase I (Other) 2 countries
An Open-label Dose-Escalation Study to Evaluate XmAb24306 as a Single Agent and in Combination with Atezolizumab in Patients with Locally Ad… Ended

2023-506285-31-00 Phase I 4 countries
To Study the Safety and Pharmacokinetics of BLYG8824A in Patients with Locally Advanced or Metastatic Colorectal Cancers Ended

2023-503409-12-00 Phase I 1 country
Dose-Escalation Study of Cevostamab in Participants with Relapsed or Refractory Multiple Myeloma Ended

2022-502053-34-00 Phase I 1 country
A Study to evaluate the Efficacy and Safety of RO7198457 in Combination With Pembrolizumab Versus Pembrolizumab in Patients with Previously … Ended

2023-507389-15-00 Phase II 2 countries AUTOGENE CEVUMERAN; PEMBROLIZUMAB
A Study to Assess Tiragolumab in Combination With Atezolizumab in Chemotherapy-Naïve Patients With Locally Advanced or Metastatic Non-Small … Ended

2023-508083-30-00 Phase II 2 countries ATEZOLIZUMAB; TIRAGOLUMAB
A Study to Evaluate Safety and Pharmacokinetics of RO7198457 as a Single Agent and in Combination with Atezolizumab in Patients with Locally… Ended

2023-504224-26-00 Phase I 2 countries

Showing 25–35 of 35 trials

← All sponsors A–Z